Go or no go? Apellis and Heron head for the finish line

Next month, Apellis’s rare severe anaemia treatment pegcetacoplan is expected to be approved, but it could have a hard time competing in a crowded market. Meanwhile, Heron will have another crack at the US after two previous knockbacks for its post-operative pain therapy HTX-011.